BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Entry into a Material Definitive Agreement
|Entry into a Material Definitive Agreement.|
On June 13, 2017, Bio-Path Holdings, Inc. (the Company) entered
into amendments (the Warrant Amendments) with certain holders
(the Holders) of the Companys outstanding warrants to purchase
common stock issued on July 5, 2016. The Warrant Amendments
provide that (i) the Holders right to require the Company to
purchase the outstanding warrants upon the occurrence of certain
fundamental transactions will not apply if the fundamental
transaction is a result of a transaction that has not been
approved by the Companys board of directors and (ii) in the event
the Company does not have an effective registration statement
registering the issuance of the underlying shares of the Companys
common stock to the Holders, there is no circumstance that would
require the Company to net cash settle the outstanding warrants.
The description of the Warrant Amendments set forth herein does
not purport to be complete and is qualified in its entirety by
reference to the full text of the form of Warrant Amendment,
which is attached hereto as Exhibit 4.1.
|Item 9.01||Financial Statements and Exhibits.|
|4.1||Form of Warrant Amendment|
BIO-PATH HOLDINGS INC ExhibitEX-4.1 2 v469208_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 AMENDMENT TO COMMON STOCK PURCHASE WARRANT This Amendment to Common Stock Purchase Warrant (this “Amendment”) is dated as of June 13,…To view the full exhibit click
here About BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH)
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.